WEST

Generate Collection

L5: Entry 1 of 22 File: USPT May 23, 2000

DOCUMENT-IDENTIFIER: US 6066645 A
TITLE: Formulations and methods of reducing toxicity of antineoplastic agents

BSPV:
7. Camptothecins--Irinotecan, Topotecan, 9-Amino Camptothecin, 10,11-Methylenedioxy Camptothecin, 9-Nitro Camptothecin, TAS 103;

WEST

End of Result Set

☐ Generate Collection

L4: Entry 4 of 4 File: USPT Oct 19, 1999

DOCUMENT-IDENTIFIER: US 5968914 A
TITLE: Treatment of chemotherapeutic agent and antiviral agent toxicity with acylated pyrimidine nucleosides

BSPR:
In addition to reduction of toxicity of antineoplastic nucleoside analogs, acyl derivatives of nonmethylated pyrimidine nucleosides are also useful for reduction of toxicity of antineoplastic agents that are cleared from the body via glucuronidation. Antineoplastic agents that are eliminated by glucuronidation include but are not limited to epirubicin and camptothecins like irinotecan and topotecan. In this process, glucuronic acid is attached to toxic compounds to facilitate their elimination. Uridine diphosphoglucuronic acid (UDPGA) is necessary for attachment of glucuronic acid to other molecules. Administration of an acyl derivative of either uridine or cytidine increases cellular UDPGA levels and thereby enhances glucuronidation of toxic compounds. In this situation, the acyl derivative of cytidine or uridine is administered before or at the same time as the antineoplastic agent. In a typical clinical situation, 1 to 10 grams of an acyl derivative of uridine is administered once to four times prior to or during administration of the antineoplastic compound.